New Stock News | Xinhehua Passes HKEX Hearing, Ranks 2nd in China by 2025 Revenue from Traditional Chinese Medicine Decoction Pieces Products

Zhitong Finance APP has learned that according to the disclosure by the Hong Kong Stock Exchange on October 25, Sichuan New Lotus Traditional Chinese Medicine Decoction Pieces Co., Ltd. (referred to as: New Lotus) has passed the listing hearing of the Hong Kong Stock Exchange Main Board, with GF Securities and Agricultural Bank International as joint sponsors. According to the prospectus, New Lotus is a supplier of large-scale traditional Chinese medicine ("TCM") decoction piece products (i) in China. According to Frost & Sullivan, based on 2025 revenue from TCM decoction piece products, New Lotus ranks 2nd in China, holding a 0.4% market share in a highly competitive market landscape, while the top five market participants collectively hold a 2.7% market share.